Mycophenolate Mofetil/Mycophenolate Sodium

First approved in the United States in 1995 for use in kidney transplantation. It can be used in combination with other immunosuppressant’s.

Biomyf is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants

Mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune disease. Unlike another immunosuppressant class, the calcineurin inhibitors, MMF generally does not cause nephrotoxicity or fibrosis

Therapy Area: Transplant
Form: Tablet
Packaging: 1x10 Strip


Mycophenolate Mofetil 500mg / Mycophenolate Sodium 360mg


Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine-5′-monophosphate dehydrogenase.

MPA depletes guanosine nucleotides preferentially in T and B lymphocytes and inhibits their proliferation, there by suppressing cell-mediated immune responses and antibody formation.

The active metabolite of mycophenolate, mycophenolic acid, prevents T-cell and B-cell proliferation and the production of cytotoxic T-cells and antibodies. Lymphocyte and monocyte adhesion to endothelial cells of blood vessels that normally part of inflammation is prevented via the glycosylation of cell adhesion molecules by MPA. MPA inhibits de novo purine biosynthesis (that promotes immune cell proliferation) by inhibiting inosine 5’-monophosphate dehydrogenase enzyme (IMPDH), with a preferential inhibition of IMPDH II. Mycophenolate mofetil reduces de-novo production of guanosine nucleotides, interfering with the synthesis of DNA, RNA, and protein required for immune cell production


  • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants.
  • Treatment of refractory rejection in patients receiving allogeneic liver or kidney transplants.
  • Systemic lupus erythematosus
  • Pemphigus vulgaris
  • Pemphigus vulgaris
  • Myasthenia gravis
  • Polymyositis
  • Polymyositis
  • Sjögren's disease
  • Uveitis and vasculitis


Kidney Transplant

Prophylaxis of organ rejection in patients receiving allogeneic renal transplants; use concomitantly with cyclosporine and corticosteroids

Mycophenolate mofetil (MMF): 1 g PO/IV q12hr, infused over ≥2 hours



Renal impairment

  • MMF: In severe renal impairment (glomerular filtration rate [GFR] <25

mL/min/1.73 m²), not to exceed 1 g q12hr

  • No dosage adjustment needed in renal transplant patients experiencing delayed graft function postoperatively

Lupus Nephritis (Off-label)

  • Induction therapy for lupus nephritis (MMF)
  • Induction: 1 g PO q12hr with a glucocorticoid or 2-3 g for 6 months with glucocorticoids
  • Maintenance: 0.5-3 g/day or 1 g PO q12hr or 1-2 g daily
  • Administer with initial IV corticosteroid pulse for 3 days, then prednisone 0.5-1 mg/kg/day PO; not to exceed 10 mg/day; after a few weeks, prednisone may be tapered to lowest effective dose


This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About Biomyf/S

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.